‘Encouraging’ results for potential disease-modifying ALS drug
New clinical data have shown that TikoMed’s low molecular weight dextran sulfate compound ILB is safe and well tolerated in patients with amyotrophic lateral sclerosis (ALS).
The trial was carried out at the Queen Elizabeth Hospital, Birmingham, UK, by the University of Birmingham’s Drugs, Devices, Diagnostics and Biomarkers (D3B) team.
Eleven patients participated in the Phase II clinical trial encompassing long-term weekly ILB injections for up to 48 weeks of 2mg/kg, a dose that was twice that used in a previously published shorter term clinical safety study.
The principal investigator of the Birmingham trial, Venkataramanan Srinivasan, MRCP (Neurology) of the Queen Elizabeth Hospital commented: “This trial demonstrated the good safety profile of long-term weekly injected ILB in patients with ALS. I am very grateful for the engaging participation by the patients in especially difficult circumstances due to the onset of the pandemic during the trial period.”
ALSFRS-R score, a predictor of survival time, and ALSAQ-40 score, a disease-specific health-related quality of life instrument, changed minimally over the 48-week reporting period which may indicate a slowing of disease progression in this small patient cohort.
TikoMed’s Scientific Advisor, Professor Ann Logan, Honorary Professor of Regenerative Medicine at the University of Warwick, added: “Taken together, the previous study at the Sahlgrenska Hospital in Gothenburg and the more recent Birmingham trial demonstrate the safety and tolerability of ILB in patients with ALS and further suggest a long-term slowing of disease progression in addition to the already reported rapid improvements in patient biochemistry and residual motor function.
“The delivery of fast functional benefit alongside long-term disease stabilisation would make ILB a unique treatment option for this devastating disease. These encouraging results indicate the future potential of ILB to be the first disease-modifying drug to treat both familial and sporadic ALS with minimal side-effects.”
Diana Spencer, Senior Digital Content Editor, DDW
